<DOC>
	<DOCNO>NCT00641615</DOCNO>
	<brief_summary>The purpose study evaluate safety immune response different dose RNF43-721 emulsify Montanide ISA 51 combination S-1/CPT-11 chemotherapy .</brief_summary>
	<brief_title>Peptide Vaccine S-1/CPT-11 Therapy Patients With Unresectable Advanced Colorectal Cancer</brief_title>
	<detailed_description>RNF43 cancer testis antigen express widely colorectal cancer tissue normal organ . RNF43-721 induces HLA A24 restrict specific cytotoxic T lymphocytes ( CTL ) RNF43 express target . S-1/CPT-11 chemotherapy perform unresectable advanced colorectal cancer Japan report obtain almost result compare FOLFOX FOLFIRI first-line chemotherapy advance colorectal cancer . Because synergistic effect vaccine therapy chemotherapy expect , plan phase I study evaluate safety immune response different dose RNF43-721 emulsify Montanide ISA 51 combination S-1/CPT-11 chemotherapy .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<criteria>ECOG performance status 01 Life expectancy &gt; 3 month HLA A24 positive Histologically diagnose colorectal cancer measurable lesion Laboratory value follow : WBC &gt; 3000/mm3 , Hb &gt; 10mg/dl , Plt &gt; 75000/mm3 , Creatinine &lt; 1.2mg/dl , T. bil. &lt; 1.5mg/dl , AST , ALT &lt; 3x normal limit Able willing give valid write informed consent Active malignancy Active infection Immune deficiency Current treatment steroid immunosuppressive agent Pregnancy breast feeding Inability oral intake Psychic disease Hepatitis B , C virus HIV infection</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>